Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study
Background Patient adherence to treatment is key to preventing the worsening of neurological disability in multiple sclerosis (MS). The RebiSmart® autoinjector facilitates self-administration of subcutaneous interferon β-1a (sc IFN β-1a) and records objective adherence data. The CORE study was under...
Gespeichert in:
| Veröffentlicht in: | BMC neurology Jg. 17; H. 1; S. 171 - 5 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London
BioMed Central
04.09.2017
BMC |
| Schlagworte: | |
| ISSN: | 1471-2377, 1471-2377 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Background
Patient adherence to treatment is key to preventing the worsening of neurological disability in multiple sclerosis (MS). The RebiSmart® autoinjector facilitates self-administration of subcutaneous interferon β-1a (sc IFN β-1a) and records objective adherence data. The CORE study was undertaken to evaluate the relationship between subjectively reported and objective adherence of MS patients using RebiSmart® in Switzerland and explore variables associated with objective adherence.
Methods
Patients with relapsing-remitting MS who were treated with sc IFN β-1a 44 or 22 μg three times weekly using RebiSmart® for at least 9 months participated in this phase IV non-interventional study. Neurologist questionnaires were used at month 0 to collect patient demographics, medical history and estimates of patients’ adherence. Patient questionnaires were used to record subjective patient-reported adherence at month 0 and estimates of variables influencing adherence. Objective adherence data were obtained from the RebiSmart® log-files at months 0 and 6.
Results
Of 56 patients who completed the observation period, 53 had evaluable data. Objective adherence differed significantly between self-reported compliant (
n
= 33) and non-compliant groups (
n
= 20) (
p
= 0.00001). Older age, greater disability, patient’s perception of the importance of ease of use and storage, being well informed about RebiSmart® features and neurologists’ estimations of adherence were all positively associated with treatment adherence.
Conclusions
We showed for the first time that subjective patient-reported adherence in MS was well in line with objective adherence, suggesting that the frequency of administration is reported accurately by patients to their neurologist. This observation may have implications for future treatment monitoring strategies and strategic medical decisions. Patients, particularly those who are younger and with lower levels of disability, may benefit from being better informed of the importance of being adherent to their treatments and receiving information about their medication and the device they are using. |
|---|---|
| AbstractList | Abstract Background Patient adherence to treatment is key to preventing the worsening of neurological disability in multiple sclerosis (MS). The RebiSmart® autoinjector facilitates self-administration of subcutaneous interferon β-1a (sc IFN β-1a) and records objective adherence data. The CORE study was undertaken to evaluate the relationship between subjectively reported and objective adherence of MS patients using RebiSmart® in Switzerland and explore variables associated with objective adherence. Methods Patients with relapsing-remitting MS who were treated with sc IFN β-1a 44 or 22 μg three times weekly using RebiSmart® for at least 9 months participated in this phase IV non-interventional study. Neurologist questionnaires were used at month 0 to collect patient demographics, medical history and estimates of patients’ adherence. Patient questionnaires were used to record subjective patient-reported adherence at month 0 and estimates of variables influencing adherence. Objective adherence data were obtained from the RebiSmart® log-files at months 0 and 6. Results Of 56 patients who completed the observation period, 53 had evaluable data. Objective adherence differed significantly between self-reported compliant (n = 33) and non-compliant groups (n = 20) (p = 0.00001). Older age, greater disability, patient’s perception of the importance of ease of use and storage, being well informed about RebiSmart® features and neurologists’ estimations of adherence were all positively associated with treatment adherence. Conclusions We showed for the first time that subjective patient-reported adherence in MS was well in line with objective adherence, suggesting that the frequency of administration is reported accurately by patients to their neurologist. This observation may have implications for future treatment monitoring strategies and strategic medical decisions. Patients, particularly those who are younger and with lower levels of disability, may benefit from being better informed of the importance of being adherent to their treatments and receiving information about their medication and the device they are using. Patient adherence to treatment is key to preventing the worsening of neurological disability in multiple sclerosis (MS). The RebiSmart® autoinjector facilitates self-administration of subcutaneous interferon β-1a (sc IFN β-1a) and records objective adherence data. The CORE study was undertaken to evaluate the relationship between subjectively reported and objective adherence of MS patients using RebiSmart® in Switzerland and explore variables associated with objective adherence. Patients with relapsing-remitting MS who were treated with sc IFN β-1a 44 or 22 μg three times weekly using RebiSmart® for at least 9 months participated in this phase IV non-interventional study. Neurologist questionnaires were used at month 0 to collect patient demographics, medical history and estimates of patients' adherence. Patient questionnaires were used to record subjective patient-reported adherence at month 0 and estimates of variables influencing adherence. Objective adherence data were obtained from the RebiSmart® log-files at months 0 and 6. Of 56 patients who completed the observation period, 53 had evaluable data. Objective adherence differed significantly between self-reported compliant (n = 33) and non-compliant groups (n = 20) (p = 0.00001). Older age, greater disability, patient's perception of the importance of ease of use and storage, being well informed about RebiSmart® features and neurologists' estimations of adherence were all positively associated with treatment adherence. We showed for the first time that subjective patient-reported adherence in MS was well in line with objective adherence, suggesting that the frequency of administration is reported accurately by patients to their neurologist. This observation may have implications for future treatment monitoring strategies and strategic medical decisions. Patients, particularly those who are younger and with lower levels of disability, may benefit from being better informed of the importance of being adherent to their treatments and receiving information about their medication and the device they are using. Background Patient adherence to treatment is key to preventing the worsening of neurological disability in multiple sclerosis (MS). The RebiSmart® autoinjector facilitates self-administration of subcutaneous interferon β-1a (sc IFN β-1a) and records objective adherence data. The CORE study was undertaken to evaluate the relationship between subjectively reported and objective adherence of MS patients using RebiSmart® in Switzerland and explore variables associated with objective adherence. Methods Patients with relapsing-remitting MS who were treated with sc IFN β-1a 44 or 22 μg three times weekly using RebiSmart® for at least 9 months participated in this phase IV non-interventional study. Neurologist questionnaires were used at month 0 to collect patient demographics, medical history and estimates of patients’ adherence. Patient questionnaires were used to record subjective patient-reported adherence at month 0 and estimates of variables influencing adherence. Objective adherence data were obtained from the RebiSmart® log-files at months 0 and 6. Results Of 56 patients who completed the observation period, 53 had evaluable data. Objective adherence differed significantly between self-reported compliant ( n = 33) and non-compliant groups ( n = 20) ( p = 0.00001). Older age, greater disability, patient’s perception of the importance of ease of use and storage, being well informed about RebiSmart® features and neurologists’ estimations of adherence were all positively associated with treatment adherence. Conclusions We showed for the first time that subjective patient-reported adherence in MS was well in line with objective adherence, suggesting that the frequency of administration is reported accurately by patients to their neurologist. This observation may have implications for future treatment monitoring strategies and strategic medical decisions. Patients, particularly those who are younger and with lower levels of disability, may benefit from being better informed of the importance of being adherent to their treatments and receiving information about their medication and the device they are using. Patient adherence to treatment is key to preventing the worsening of neurological disability in multiple sclerosis (MS). The RebiSmart® autoinjector facilitates self-administration of subcutaneous interferon β-1a (sc IFN β-1a) and records objective adherence data. The CORE study was undertaken to evaluate the relationship between subjectively reported and objective adherence of MS patients using RebiSmart® in Switzerland and explore variables associated with objective adherence.BACKGROUNDPatient adherence to treatment is key to preventing the worsening of neurological disability in multiple sclerosis (MS). The RebiSmart® autoinjector facilitates self-administration of subcutaneous interferon β-1a (sc IFN β-1a) and records objective adherence data. The CORE study was undertaken to evaluate the relationship between subjectively reported and objective adherence of MS patients using RebiSmart® in Switzerland and explore variables associated with objective adherence.Patients with relapsing-remitting MS who were treated with sc IFN β-1a 44 or 22 μg three times weekly using RebiSmart® for at least 9 months participated in this phase IV non-interventional study. Neurologist questionnaires were used at month 0 to collect patient demographics, medical history and estimates of patients' adherence. Patient questionnaires were used to record subjective patient-reported adherence at month 0 and estimates of variables influencing adherence. Objective adherence data were obtained from the RebiSmart® log-files at months 0 and 6.METHODSPatients with relapsing-remitting MS who were treated with sc IFN β-1a 44 or 22 μg three times weekly using RebiSmart® for at least 9 months participated in this phase IV non-interventional study. Neurologist questionnaires were used at month 0 to collect patient demographics, medical history and estimates of patients' adherence. Patient questionnaires were used to record subjective patient-reported adherence at month 0 and estimates of variables influencing adherence. Objective adherence data were obtained from the RebiSmart® log-files at months 0 and 6.Of 56 patients who completed the observation period, 53 had evaluable data. Objective adherence differed significantly between self-reported compliant (n = 33) and non-compliant groups (n = 20) (p = 0.00001). Older age, greater disability, patient's perception of the importance of ease of use and storage, being well informed about RebiSmart® features and neurologists' estimations of adherence were all positively associated with treatment adherence.RESULTSOf 56 patients who completed the observation period, 53 had evaluable data. Objective adherence differed significantly between self-reported compliant (n = 33) and non-compliant groups (n = 20) (p = 0.00001). Older age, greater disability, patient's perception of the importance of ease of use and storage, being well informed about RebiSmart® features and neurologists' estimations of adherence were all positively associated with treatment adherence.We showed for the first time that subjective patient-reported adherence in MS was well in line with objective adherence, suggesting that the frequency of administration is reported accurately by patients to their neurologist. This observation may have implications for future treatment monitoring strategies and strategic medical decisions. Patients, particularly those who are younger and with lower levels of disability, may benefit from being better informed of the importance of being adherent to their treatments and receiving information about their medication and the device they are using.CONCLUSIONSWe showed for the first time that subjective patient-reported adherence in MS was well in line with objective adherence, suggesting that the frequency of administration is reported accurately by patients to their neurologist. This observation may have implications for future treatment monitoring strategies and strategic medical decisions. Patients, particularly those who are younger and with lower levels of disability, may benefit from being better informed of the importance of being adherent to their treatments and receiving information about their medication and the device they are using. |
| ArticleNumber | 171 |
| Author | Zecca, Chiara Mühl, Sarah Gobbi, Claudio Disanto, Giulio |
| Author_xml | – sequence: 1 givenname: Chiara surname: Zecca fullname: Zecca, Chiara organization: Multiple Sclerosis Center, Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano – sequence: 2 givenname: Giulio surname: Disanto fullname: Disanto, Giulio organization: Multiple Sclerosis Center, Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano – sequence: 3 givenname: Sarah surname: Mühl fullname: Mühl, Sarah organization: Merck (Schweiz) AG – sequence: 4 givenname: Claudio surname: Gobbi fullname: Gobbi, Claudio email: Claudio.Gobbi@eoc.ch organization: Multiple Sclerosis Center, Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Multiple Sclerosis Center, Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28870152$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UktuFDEQbaEg8oEDsEFesmmw3e22zQIJjQJEihQpgbXlT_WMRz3twXaPlFPkJiw4AgfgTHjoJEpYZGWr6r1XT1XvuDoYwwhV9Zrgd4SI7n0iVIimxoTXWDJay2fVEWk5qWnD-cGD_2F1nNIaF6BoyYvqsNA4JoweVTdXk1mDzX4HaKuzhzHXEbYhZnBoBzFNCYV7hHYriDBaQDmgNBk7ZT1CKBg_Zog9xDCiP79qoksBbaYh--0AKNmhdJJPaEp-XKJLMP5qo2P-_fMDyitAi4vLU5Ty5K5fVs97PSR4dfueVN8_n35bfK3PL76cLT6d17aljaxFbw0Hwnjbd7xzBiRn0DktjRWGEmEEpq2kkjHQ2lDZ9Ny0zrquxRb3tG9OqrNZ1wW9Vtvoi51rFbRX_wohLlXx54txJZ0QtsfWYiJbzohowdCmp66hrWbMFa2Ps9Z2Mhtwtuww6uGR6OPO6FdqGXaKMdEWn0Xg7a1ADD8mSFltfLIwDPNyFZENE6SjXVegbx7Ouh9yd9EC4DPAlo2nCL2yPpfDhv1oPyiC1T47as6OKpFQ--woWZjkP-ad-FMcOnNSwY5LiGodpjiWyz1B-gskENto |
| CitedBy_id | crossref_primary_10_7224_1537_2073_2021_139 crossref_primary_10_1007_s00415_021_10850_w crossref_primary_10_1007_s40120_024_00593_x crossref_primary_10_1016_j_msard_2020_101951 crossref_primary_10_1186_s12883_021_02149_0 crossref_primary_10_1016_j_msard_2023_105097 crossref_primary_10_3390_ijerph19042203 |
| Cites_doi | 10.1517/17425247.2015.1057567 10.2165/11533330-000000000-00000 10.1371/journal.pone.0145076 10.1371/journal.pone.0133279 10.1371/journal.pone.0059694 10.1517/17425247.2015.1078789 10.4081/ni.2017.6957 10.2147/PPA.S127508 10.3322/caac.20004 10.1517/17425247.2016.1158161 10.18553/jmcp.2013.19.s1.S24 10.1517/17425247.2013.746311 10.1517/17425247.2016.1148029 10.1007/s00415-009-0096-y 10.4104/pcrj.2011.00056 10.1016/S0025-7753(02)73341-1 10.1111/j.1468-1331.2010.03110.x 10.1007/s00415-008-2001-5 10.7326/0003-4819-157-11-201212040-00538 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2017 |
| Copyright_xml | – notice: The Author(s). 2017 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1186/s12883-017-0952-9 |
| DatabaseName | Springer Open Access Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2377 |
| EndPage | 5 |
| ExternalDocumentID | oai_doaj_org_article_9d88cf0cc019475184eb23f2d324a55d PMC5584024 28870152 10_1186_s12883_017_0952_9 |
| Genre | Multicenter Study Journal Article Comparative Study |
| GrantInformation_xml | – fundername: Merck KGaA funderid: http://dx.doi.org/10.13039/100009945 – fundername: ; |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABIVO ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IGS IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION -A0 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c4239-8fcb7e1574f676dbe975e6da9bc8b218b802492955eaab293f7b4dcd640c0f2f3 |
| IEDL.DBID | DOA |
| ISSN | 1471-2377 |
| IngestDate | Fri Oct 03 12:44:34 EDT 2025 Tue Nov 04 01:42:16 EST 2025 Fri Sep 05 13:48:32 EDT 2025 Thu Jan 02 23:10:21 EST 2025 Tue Nov 18 21:49:22 EST 2025 Sat Nov 29 01:39:51 EST 2025 Sat Sep 06 07:22:26 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Adherence Multiple sclerosis Self-reported adherence Subjective adherence RebiSmart Objective adherence sc IFN β-1a Patient adherence Subcutaneous interferon β-1a Autoinjector |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4239-8fcb7e1574f676dbe975e6da9bc8b218b802492955eaab293f7b4dcd640c0f2f3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://doaj.org/article/9d88cf0cc019475184eb23f2d324a55d |
| PMID | 28870152 |
| PQID | 1935816266 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9d88cf0cc019475184eb23f2d324a55d pubmedcentral_primary_oai_pubmedcentral_nih_gov_5584024 proquest_miscellaneous_1935816266 pubmed_primary_28870152 crossref_citationtrail_10_1186_s12883_017_0952_9 crossref_primary_10_1186_s12883_017_0952_9 springer_journals_10_1186_s12883_017_0952_9 |
| PublicationCentury | 2000 |
| PublicationDate | 20170904 |
| PublicationDateYYYYMMDD | 2017-09-04 |
| PublicationDate_xml | – month: 9 year: 2017 text: 20170904 day: 4 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationSubtitle | BMC series – open, inclusive and trusted |
| PublicationTitle | BMC neurology |
| PublicationTitleAbbrev | BMC Neurol |
| PublicationTitleAlternate | BMC Neurol |
| PublicationYear | 2017 |
| Publisher | BioMed Central BMC |
| Publisher_xml | – name: BioMed Central – name: BMC |
| References | SC Steinberg (952_CR4) 2010; 30 952_CR14 A Bayas (952_CR10) 2015; 12 VG Jokubaitis (952_CR16) 2013; 8 J Menzin (952_CR5) 2013; 19 K Ruddy (952_CR20) 2009; 59 K Hansen (952_CR7) 2015; 10 F Depont (952_CR8) 2015; 10 F Puigventos (952_CR19) 2002; 119 MD Edo Solsona (952_CR12) 2017; 11 K Treadaway (952_CR15) 2009; 256 M Viswanathan (952_CR2) 2012; 157 A Lugaresi (952_CR9) 2013; 10 V Devonshire (952_CR6) 2011; 18 E Jarvinen (952_CR13) 2017; 9 MR Partridge (952_CR18) 2011; 20 952_CR1 A Al-Sabbagh (952_CR3) 2008; 255 D Paolicelli (952_CR17) 2016; 13 M Moccia (952_CR11) 2015; 12 26922837 - Expert Opin Drug Deliv. 2016 Jun;13(6):799-805 19444532 - J Neurol. 2009 Apr;256(4):568-76 20561039 - Eur J Neurol. 2011 Jan;18(1):69-77 19147869 - CA Cancer J Clin. 2009 Jan-Feb;59(1):56-66 26371561 - Expert Opin Drug Deliv. 2015;12(12):1829-35 23527252 - PLoS One. 2013;8(3):e59694 26909646 - Expert Opin Drug Deliv. 2016 Jul;13(7):931-5 22964778 - Ann Intern Med. 2012 Dec 4;157(11):785-95 28286627 - Neurol Int. 2017 Feb 20;9(1):6957 20067327 - Clin Drug Investig. 2010;30(2):89-100 12106524 - Med Clin (Barc). 2002 Jun 29;119(4):130-7 26098143 - Expert Opin Drug Deliv. 2015 Aug;12(8):1239-50 26214805 - PLoS One. 2015 Jul 27;10(7):e0133279 26674526 - PLoS One. 2015 Dec 16;10(12):e0145076 21660394 - Prim Care Respir J. 2011 Sep;20(3):315-23, 17 p following 323 23252744 - Expert Opin Drug Deliv. 2013 Feb;10(2):273-83 28280313 - Patient Prefer Adherence. 2017 Mar 02;11:415-421 23383731 - J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S24-40 |
| References_xml | – volume: 12 start-page: 1239 issue: 8 year: 2015 ident: 952_CR10 publication-title: Expert Opin Drug Deliv. doi: 10.1517/17425247.2015.1057567 – volume: 30 start-page: 89 issue: 2 year: 2010 ident: 952_CR4 publication-title: Clin Drug Investig doi: 10.2165/11533330-000000000-00000 – volume: 10 start-page: e0145076 issue: 12 year: 2015 ident: 952_CR8 publication-title: PLoS One doi: 10.1371/journal.pone.0145076 – volume: 10 start-page: e0133279 issue: 7 year: 2015 ident: 952_CR7 publication-title: PLoS One doi: 10.1371/journal.pone.0133279 – volume: 8 start-page: e59694 issue: 3 year: 2013 ident: 952_CR16 publication-title: PLoS One doi: 10.1371/journal.pone.0059694 – volume: 12 start-page: 1829 issue: 12 year: 2015 ident: 952_CR11 publication-title: Expert Opin Drug Deliv. doi: 10.1517/17425247.2015.1078789 – volume: 9 start-page: 6957 issue: 1 year: 2017 ident: 952_CR13 publication-title: Neurol Int doi: 10.4081/ni.2017.6957 – volume: 11 start-page: 415 year: 2017 ident: 952_CR12 publication-title: Patient Prefer Adherence doi: 10.2147/PPA.S127508 – volume: 59 start-page: 56 issue: 1 year: 2009 ident: 952_CR20 publication-title: CA Cancer J Clin doi: 10.3322/caac.20004 – volume: 13 start-page: 799 issue: 6 year: 2016 ident: 952_CR17 publication-title: Expert Opin Drug Deliv doi: 10.1517/17425247.2016.1158161 – volume: 19 start-page: S24 issue: 1 Suppl A year: 2013 ident: 952_CR5 publication-title: J Manag Care Pharm doi: 10.18553/jmcp.2013.19.s1.S24 – volume: 10 start-page: 273 issue: 2 year: 2013 ident: 952_CR9 publication-title: Expert Opin Drug Deliv. doi: 10.1517/17425247.2013.746311 – ident: 952_CR14 doi: 10.1517/17425247.2016.1148029 – volume: 256 start-page: 568 issue: 4 year: 2009 ident: 952_CR15 publication-title: J Neurol doi: 10.1007/s00415-009-0096-y – volume: 20 start-page: 315 issue: 3 year: 2011 ident: 952_CR18 publication-title: Prim Care Respir J doi: 10.4104/pcrj.2011.00056 – volume: 119 start-page: 130 issue: 4 year: 2002 ident: 952_CR19 publication-title: Med Clin (Barc) doi: 10.1016/S0025-7753(02)73341-1 – ident: 952_CR1 – volume: 18 start-page: 69 issue: 1 year: 2011 ident: 952_CR6 publication-title: Eur J Neurol doi: 10.1111/j.1468-1331.2010.03110.x – volume: 255 start-page: S79 issue: Suppl. 2 year: 2008 ident: 952_CR3 publication-title: J Neurol doi: 10.1007/s00415-008-2001-5 – volume: 157 start-page: 785 issue: 11 year: 2012 ident: 952_CR2 publication-title: Ann Intern Med doi: 10.7326/0003-4819-157-11-201212040-00538 – reference: 26909646 - Expert Opin Drug Deliv. 2016 Jul;13(7):931-5 – reference: 23252744 - Expert Opin Drug Deliv. 2013 Feb;10(2):273-83 – reference: 26922837 - Expert Opin Drug Deliv. 2016 Jun;13(6):799-805 – reference: 28280313 - Patient Prefer Adherence. 2017 Mar 02;11:415-421 – reference: 19147869 - CA Cancer J Clin. 2009 Jan-Feb;59(1):56-66 – reference: 26371561 - Expert Opin Drug Deliv. 2015;12(12):1829-35 – reference: 26098143 - Expert Opin Drug Deliv. 2015 Aug;12(8):1239-50 – reference: 22964778 - Ann Intern Med. 2012 Dec 4;157(11):785-95 – reference: 23383731 - J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S24-40 – reference: 26214805 - PLoS One. 2015 Jul 27;10(7):e0133279 – reference: 26674526 - PLoS One. 2015 Dec 16;10(12):e0145076 – reference: 12106524 - Med Clin (Barc). 2002 Jun 29;119(4):130-7 – reference: 20067327 - Clin Drug Investig. 2010;30(2):89-100 – reference: 28286627 - Neurol Int. 2017 Feb 20;9(1):6957 – reference: 20561039 - Eur J Neurol. 2011 Jan;18(1):69-77 – reference: 23527252 - PLoS One. 2013;8(3):e59694 – reference: 19444532 - J Neurol. 2009 Apr;256(4):568-76 – reference: 21660394 - Prim Care Respir J. 2011 Sep;20(3):315-23, 17 p following 323 |
| SSID | ssj0017841 |
| Score | 2.1924675 |
| Snippet | Background
Patient adherence to treatment is key to preventing the worsening of neurological disability in multiple sclerosis (MS). The RebiSmart® autoinjector... Patient adherence to treatment is key to preventing the worsening of neurological disability in multiple sclerosis (MS). The RebiSmart® autoinjector... Abstract Background Patient adherence to treatment is key to preventing the worsening of neurological disability in multiple sclerosis (MS). The RebiSmart®... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 171 |
| SubjectTerms | Adherence Adjuvants, Immunologic - administration & dosage Adult Autoinjector Demyelinating diseases Disabled Persons Female Humans Injections, Subcutaneous Interferon beta-1a - administration & dosage Male Medication Adherence - statistics & numerical data Medicine Medicine & Public Health Middle Aged Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis, Relapsing-Remitting - drug therapy Neurochemistry Neurologists Neurology Neurosurgery Patient Compliance RebiSmart Research Article sc IFN β-1a Self Administration Self Medication - instrumentation Self Report Subcutaneous interferon β-1a Surveys and Questionnaires |
| SummonAdditionalLinks | – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEB5BQYgL_4XwJyNxAlkkWTt2uEHVigMU1ELVm-XfdhFNqmSX1-BNOPAIPADPxNhJVlooSHDZQ3asOOOZ8Rd9k88Aj2e5RxQfO9VmglHEtxU1VuOPLwOrtc_rJMdw8Frs7srDw_rd-B13P3W7T5RkqtQprWX1rC_iwbg0VlWEBSWtz8MF3O1kzMa9_YMVdRCJtJG-PHPY2gaUdPrPApe_90j-QpSm_Wfn6n_N_BpcGeEmeTHEx3U455sbcOnNSKjfhC9YOD4ONY-MEqt0oBG8I7FjY9mTdmWh3fHwdSBZtKRfGrtEaOlbtImqE13wXduQH99oofECmXoVSY-3Rl_MexK77I8ILul8_wRj9vvX5wQBKNl6u7dNktDtLfiws_1-6xUdz2igNkoHUhmsEb7ggoVKVM74WnBfOV0bKw3CByOTJmHNudfaILYIwjBnXcVym4cyzDZho2kbfwcI5zje5MIJy5mwRjrDcl04EyyCHC0zyKeFU3YUMI_naHxS6UVGVmpwtEJHq-hoVWfwZDXkdFDv-JvxyxgNK8MovJ0utN2RGvNY1U5KG3JrERqzSFkxb8pZKB0CU825y-DRFEsKEzWyL8NCqCJJzeH7Y5XB7SG2VrfCmQjEZWUGYi3q1uay_k8zP05i4BwRJLo4g6dT7KmxCvV_ftS7_2R9Dy6XQ_DSnN2HjUW39A_gov28mPfdw5R9PwFKcjBk priority: 102 providerName: Springer Nature |
| Title | Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study |
| URI | https://link.springer.com/article/10.1186/s12883-017-0952-9 https://www.ncbi.nlm.nih.gov/pubmed/28870152 https://www.proquest.com/docview/1935816266 https://pubmed.ncbi.nlm.nih.gov/PMC5584024 https://doaj.org/article/9d88cf0cc019475184eb23f2d324a55d |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LjtMwFLVgQGg2iDfhURmJFciaJLVjhx0z6ggkplQdGJWV5SdTNCSoafkN_oQFn8AH8E1c22lFeW7YWLJjy497fX2se3OM0MNh7gDFh0i1IacE8G1FtFGQuNLTWrm8jnQMJy_4eCxms3ryw1NfISYs0QOnhdurrRDG58YAFqHBR0DhLjj0pQUkoBizwfoC6llfpnr_QfCm9T7MQlR7XREe1SXBIgOkKEm9dQpFsv7fIcxfAyV_8pbGQ-jwCrrco0f8NI36Kjrnmmvo0lHvH7-OPoEdeJdMGO4ZU0nyCjiLQwDGqsPtpoayp-lnP7xscbfSZgVI0bVQJ5BILLxbtA3-9oUUCgrwOvQQd9A1zGre4RA0_xaDhObH72Elv35-ggFP4oOX0xGOvLU30OvD0auDZ6R_coGYwARIhDeau4Jx6iteWe1qzlxlVa2N0IAGtIgUgzVjTikNUMFzTa2xFc1N7ks_vIl2mrZxtxFmDNrrnFtuGOVGC6tprgqrvQHMokSG8rUIpOn5yMOzGGcy3ktEJZPUJEhNBqnJOkOPNk0-JDKOv1XeD3LdVAw82rEAtEv22iX_pV0ZerDWCgn7LjhTkiBkEZnj4DpYZehW0pJNVzASDjCrzBDf0p-tsWx_aeankdubASCEJc7Q47Wmyd6odH-e6p3_MdW7aLdMG4Tk9B7aWS5W7j66aD4u591igM7zGY-pGKAL-6PxZDqIWw5yk-dHkzeQmx6ffAcalDKb |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLWgIGDDmxKeRmIFsppk7NhhB1WrIqYDakvVneVnO6gkKJnhN_gTFnwCH8A3ce08pIGCBJsskmvFub6-Pta5OUbo6SR1gOJDpdqEUwL4tiDaKLi43NNSubSMcgyHUz6biaOj8l3_H3c7VLsPlGTM1HFai2KjzcLBuCRkVYAFOSnPowsUFqxQx7e3fzhSB4FI6-nLM5utLEBRp_8scPl7jeQvRGlcf7av_VfPr6OrPdzEL7v4uIHOueomurTbE-q30BdIHB-6nId7iVXS0QjO4lCxsWxxPVooe9L9HYgXNW6X2iwBWroabILqRONdU1f4xzeSKbiBh1pF3MKrwRfzFocq-2MMQzrf_wgx-_3rCwwAFG--3dvCUej2Nnq_vXWwuUP6MxqICdKBRHijucsYp77ghdWu5MwVVpXaCA3wQYuoSVgy5pTSgC0819QaW9DUpD73kztoraordxdhxqC9TrnlhlFutLCapiqz2hsAOUokKB0GTppewDyco3Eq40ZGFLJztARHy-BoWSbo2djkU6fe8TfjVyEaRsMgvB1v1M2x7OexLK0QxqfGADSmgbKiTucTn1sApooxm6AnQyxJmKiBfekGQmZRag72j0WC1rvYGl8FPeGAy_IE8ZWoW-nL6pNqfhLFwBkgSHBxgp4PsSf7LNT--VPv_ZP1Y3R552B3KqevZ2_uoyt5F8gkpQ_Q2qJZuofoovm8mLfNozgTfwKRrTNI |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LbtQwFLWgoIoN79LwNBIrkNUkY8cOOygdgShDRaHqzvKzHUSTKpnhN_gTFnwCH8A3cR0nkQYKEmKThXMtJ9fXzrHOzbkIPZqkDlB8yFSbcEoA3xZEGwUXl3taKpeWnRzDwS6fzcThYbnX1zlth2z3gZKM_zQElaZqsXVqfVziothqs1Akl4QdFiBCTsrz6AINNYPCcX3_YKQRAqnWU5lndlv5GHWa_WcBzd_zJX8hTbtv0fTKf7_FVXS5h6H4WYyba-icq66j9Tc90X4DfYEN5WPcC3EvvUoiveAsDpkcyxbXo4Wyx_GvQbyocbvUZgmQ09VgE9QoGu-ausI_vpFMQQMechhxC0ODX-YtDtn3Rximer5_ArH8_etTDMAUb799t4M7Adyb6MN05_32S9LXbiAmSAoS4Y3mLmOc-oIXVruSM1dYVWojNMAKLTqtwpIxp5QGzOG5ptbYgqYm9bmfbKC1qq7cJsKMQX-dcssNo9xoYTVNVWa1NwB-lEhQOkyiNL2weaiv8Ul2BxxRyOhoCY6WwdGyTNDjsctpVPX4m_HzEBmjYRDk7hrq5kj261uWVgjjU2MAMtNAZVGn84nPLQBWxZhN0MMhriQs4MDKxImQWSdBB-fKIkG3YpyNQ8GTcMBreYL4SgSuPMvqnWp-3ImEM0CW4OIEPRniUPa7U_vnV739T9YP0Prei6ncfTV7fQddymMck5TeRWuLZunuoYvm82LeNve7RfkT0D48LA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Subjective+patient-reported+versus+objective+adherence+to+subcutaneous+interferon+%CE%B2-1a+in+multiple+sclerosis+using+RebiSmart%C2%AE%3A+the+CORE+study&rft.jtitle=BMC+neurology&rft.au=Chiara+Zecca&rft.au=Giulio+Disanto&rft.au=Sarah+M%C3%BChl&rft.au=Claudio+Gobbi&rft.date=2017-09-04&rft.pub=BMC&rft.eissn=1471-2377&rft.volume=17&rft.issue=1&rft.spage=1&rft.epage=5&rft_id=info:doi/10.1186%2Fs12883-017-0952-9&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_9d88cf0cc019475184eb23f2d324a55d |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2377&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2377&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2377&client=summon |